Randomized, double-blinded trial evaluation of valsartan/hydrochlorothiazide combination therapy in mild to moderate essential hypertension in North-east China

Journal of International Medical Research

Volumn 36, Issue 4, 2008, Pages 630-637

  Zhang, S ^a   Yu, B ^a   Li, L ^a   Du, Z ^a   Guan, Z ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II receptor blocker; Hydrochlorothiazide; Hypertension; Valsartan

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS VALSARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; AGED; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; HYPERTENSION; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHINA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 52049101351     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600403     Document Type: Article

References (22)

1. Liu L: Cardiovascular diseases in China. Biochem Cell Biol 2007; 85: 157-163.
2. He J, Gu D, Wu X, et al: Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124-1134.
3. Wang Z, Wu Y, Zhao L, et al: Trends in prevalence, awareness, treatment and control of hypertension in the middle-aged population of China, 1992-1998. Hypertens Res 2004; 27: 703-709.
4. Neutel JM: The use of combination drug therapy in the treatment of hypertension. Prog Cardiovasc Nurs 2002; 17: 81-88.
5. Burnier M, Santschi V, Favrat B, et al: Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens 2003; 21 (suppl): S37-S42.
6. Lacourcière Y, Poirier L, Hebert D, et al: Antihypertenslve efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27: 1013-1021.
7. Pool JL, Glazer R, Weinberger M, et al: Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007; 29: 61-73.
8. Philipp T, Smith TR, Glazer R, et al: Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563-580.
9. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
10. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2572.
11. Horan MJ, Lenfant C: Epidemiology of blood pressure and predictors of hypertension. Hypertension 1990; 15(2 suppl): 120-124.
12. Campbell NR, Burgess E, Choi BC, et al: Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999; 160 (9 suppl): S1-S6.
13. Schwartz GL, Turner ST. Pharmacogenetics of antihypertensive drug responses. Am J Pharmacogenomics 2004; 4: 151-160.
14. Giles TD: Rationale for combination therapy as initial treatment for hypertension. J Clin Hypertens (Greenwich) 2003; 5 (4 suppl 3): 4-11.
15. Mallion JM, Carretta R, Trenkwakder P, et al: Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl 2003; 1: 36-43.
16. Saruta T, Ogihara T, Matsuoka H, et al: Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res 2007; 30: 729-739.
17. Kaplan NM: Angiotensin II receptor antagonists in the treatment of hypertension. Am Fam Physician 1999; 60: 1185-1190.
18. Carter BL, Ernst ME, Cohen JD: Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9.
19. Franklin SS: Systolic blood pressure: it's time to take control. Am J Hypertens 2004; 17: 49S-59S.
20. Mancia G, Seravalle G, Grassi G: Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens 2002; 20 (suppl): S21-S27.
21. Brownley KA, Hurwitz BE, Schneiderman N: Ethnic variations in the pharmacological and nonpharmacological treatment of hypertension: biopsychosocial perspective. Hum Biol 1999; 71: 607-639.
22. Marteau JB, Zaiou M, Siest G, et al: Genetic determinants of blood pressure regulation. J Hypertens 2005; 23: 2127-2143.